LOGIN
Preoperative human recombinant erythropoietin reduces allogenic blood transfusion
May 2013
Preoperative human recombinant erythropoietin reduces allogenic blood transfusion
Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A
Two different dosing regimens of human recombinant erythropoietin beta during preoperative autologous blood donation in patients having hip arthroplasty.
Int Orthop. 2012 Apr;36(4):703-9. Epub 2011 Oct 1.Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
93 patients undergoing total hip arthroplasty were randomized to differing preoperative dosing regimes of human recombinant erythropoietin (rHu-EPO) to elucidate its affect on preoperative blood donation and intra-operative blood transfusions. Patients received either a once weekly i.v of 30000 IU rHu-EPO, a twice weekly i.v. of 15000 IU rHu-EPO, or no rHu-EPO. All groups received an oral does of ...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.